{"@context":"https://schema.org","@type":"CollectionPage","name":"#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars","description":"

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” of IP litigations between makers of branded small molecule drugs and generics requires an analysis under the rule of reason. Are there distinct challenges presented by settlements between branded biologics and biosimilars? Sean Sheridan and Archan Ruparel, principals at Charles River Associates, speak with Anora Wang and Christina Ma on the complexities of negotiating patent settlements involving biosimilars. Listen to this episode to learn about pharmaceutical entry, price erosion, and more.

With special guests:

Sean Sheridan, Principal, Charles River Associates and Archan Ruparel, Principal, Charles River Associates

Hosted by:

Anora Wang, Arnold & Porter and Christina Ma, Wachtell, Lipton, Rosen & Katz

","mainEntity":{"@type":"ItemList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@type":"CreativeWork","name":"#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars","url":"https://www.wowfm.app/sound-player/172-biologically-similar-but-competitively-not-so-economic-considerations-of-ip-litigation-settlements-involving-biosimilars-s0Bn8CF2q6#undefined"}}]}}

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

اقساط